Patient characteristics (N=117)
| No of patients | |
| Demographic characteristics | |
| Maternal age, years | 30±6.1 |
| Non-white ethnicity | 65 (55.5) |
| Federally funded insurance* | 17 (20.5) |
| Body mass index (kg/m2) | 30±5.8 |
| Prepregnancy characteristics | |
| NYHA class≥II | 16 (13.7) |
| Any prepregnancy cardiovascular event† | 28 (23.9) |
| Any prior cardiovascular intervention‡ | 85 (72.7) |
| Ejection fraction <55%* | 16 (19.3) |
| Chronic hypertension | 10 (8.6) |
| Pre-existing diabetes mellitus | 1 (1.0) |
| mWHO group>II | 63 (53.8) |
| CARPREG score≥1 | 33 (28.2) |
| CARPREG II score 0–2 | 84 (71.8) |
| CARPREG II score≥3 | 31 (28.2) |
| ZAHARA score 0–0.50 | 57 (48.7) |
| ZAHARA score 0.51–1.50 | 27 (23.1) |
| ZAHARA score≥1.51 | 33 (28.2) |
| Any prepregnancy cardiac medication§ | 25 (21.4) |
| Prepregnancy aspirin use | 24 (20.5) |
| Pregnancy-related events | |
| Any antepartum cardiovascular event† | 14 (12.0) |
| Any postpartum¶ cardiovascular event† | 4 (3.4) |
Data for continuous variables presented as median±IQR.
Data for dichotomous variables presented as N (%).
*Total N=83 due to missing data.
†Includes prepregnancy congestive heart failure, arrhythmia, thromboembolic or cerebrovascular event.
‡Includes surgical, transcatheter or arrhythmic intervention.
§Includes ACE inhibitor, diuretic, beta blocker, anticoagulant, digoxin.
¶Delivery through 6 months post partum.
CARPREG, Cardiac Disease in Pregnancy Study; mWHO, modified WHO classification ; NYHA, New York Heart Association; ZAHARA, Zwangerschap bij Aangeboren HARtAfwijking.